INS and type 2 diabetes mellitus: Non-inferiority in terms of efficacy, compared to standard basal insulin treatment, was confirmed by 6 phase III RCTs that involved more than 4000 patients affected by diabetes mellitus; furthermore, superiority of insulin icodec was confirmed in insulin-naïve T2DM patients where safety profile was demonstrated to be comparable to that of standard basal insulins without additional risks.